Home › Compound Library › Atorvastatin (Lipitor)

Atorvastatin (Lipitor)

Statinprescriptionoral · inferred

HMG-CoA reductase inhibitor for cholesterol management. Active metabolites (ortho- and para-hydroxy) are equipotent and account for ~70% of total inhibitory activity.

Projected serum levels — 20 mg, once daily

Atorvastatin (Lipitor)
Atorvastatin (Lipitor) modeled serum levels, 20 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 20 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 1.0 mg, trough ≈ 0.005 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Statin
Route modeled
Oral
Model confidence
inferred
Half-life
14 h
Common dose
20 mg
Suggested maximum
80 mg/day
Reference dose range
5–80 mg (single dose)
Suggested cadence
once daily
Validated against
40 mg oral — Cmax 0.027 mg/L at 1.5 h

Documented interactions

  • contraindicated
    Efavirenz (Sustiva) + Atorvastatin (Lipitor) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~0.16x

  • contraindicated
    Rifampin + Atorvastatin (Lipitor) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~0.16x

  • danger
    Amlodipine (Norvasc) + Atorvastatin (Lipitor) CYP inhibition

    Amlodipine (Norvasc) reversible_inhibitor of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~2.07x

  • danger
    Ashwagandha (KSM-66) + Atorvastatin (Lipitor) CYP inhibition

    Ashwagandha (KSM-66) reversible_inhibitor of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~2.07x

  • danger
    Berberine + Atorvastatin (Lipitor) CYP inhibition

    Berberine reversible_inhibitor of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~2.07x

  • danger
    Black Seed Oil (Nigella sativa / Thymoquinone) + Atorvastatin (Lipitor) CYP inhibition

    Black Seed Oil (Nigella sativa / Thymoquinone) reversible_inhibitor of CYP3A4 predicted to change Atorvastatin (Lipitor) AUC by ~2.07x

Serum checks 241 modeled interaction pairings for atorvastatin (lipitor) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations (ASCOT-LLA) Sever PS et al. · Lancet, 2003 DOI

    RCT of 10,305 patients found atorvastatin 10 mg reduced fatal and non-fatal stroke by 27% and total cardiovascular events by 21% in hypertensive patients with normal cholesterol.

  2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT-TIMI 22) Cannon CP et al. · New England Journal of Medicine, 2004 DOI

    Landmark trial of 4,162 acute coronary syndrome patients found atorvastatin 80 mg reduced death and major cardiovascular events by 16% compared to pravastatin 40 mg.

  3. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Cholesterol Treatment Trialists Collaboration · Lancet, 2010 DOI

    Meta-analysis of 26 statin trials found each 1 mmol/L LDL reduction reduced major vascular events by 22%, major coronary events by 24%, and stroke by 15%.

3 published studies referenced in the app, each with a plain-language summary.